Modality
siRNA
MOA
CD47i
Target
GPRC5D
Pathway
Hedgehog
MCCUCGIST
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
Jul 2017
→ Jun 2028
Phase 2Current
NCT08507964
603 pts·GIST
2017-07→2028-06·Terminated
603 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-092.2y awayPh2 Data· GIST
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Termina…
Catalysts
Ph2 Data
2028-06-09 · 2.2y away
GIST
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08507964 | Phase 2 | GIST | Terminated | 603 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Zenonesiran | GSK | Preclinical | DLL3 |